News

During the American College of Cardiology (ACC) Congress held this March (14-16) in San Diego, data from the pivotal Selexipag (Uptravi®) Phase III GRIPHON study was shared in an oral presentation. The presentation, entitled “Effect of selexipag on morbidity/mortality in pulmonary arterial hypertension: results of the GRIPHON study” was presented by Dr. Vallerie V.

Findings from a recent study presented this week during the American College of Cardiology/i2 Scientific Session revealed that denervation of the pulmonary artery through catheterization led to a decline in pulmonary arterial hypertension (PAH)-related events and an improvement in heart function and hemodynamic variables in patients with pulmonary hypertension. The…

Researchers at the Cleveland Clinic recently published findings in the journal Circulation revealing that a protein linked to the glucose metabolism pathway can promote cellular proliferation in lung tissues of individuals with idiopathic pulmonary arterial hypertension (IPAH). The study is entitled “O-GlcNAc Transferase…

Results from a recent study published in the Egyptian Journal of Chest Diseases and Tuberculosis suggest that Pulmonary hypertension (PH) in patients with Chronic Obstructive Pulmonary Disease (COPD) is a common co-morbidity along with right sided cardiac changes. Based on the findings, the researchers suggest that…

Biopharmaceutical company Pulmokine has entered into a $1 million investment agreement with Broadview Ventures. The partnership is meant to accelerate the development of the lead drug candidate being developed by Pulmokine, PK10571, for the treatment of pulmonary arterial hypertension (PAH) and enable the initiation of its phase 1 clinical trial. The CEO…

Canadian patients who suffer from pulmonary arterial hypertension (PAH) are raising concerns about the risk of heart failure and death associated with the disease due to a new recommendation from the Common Drug Review (CDR) to limit the access of Opsumit (macitentan) to newly diagnosed patients. The alert…

According to a recent study published online in the American Journal of Managed Care, PH-related hospitalizations lead to high healthcare costs, with patients with PAH requiring long hospital stays. The study results also revealed that many patients with PAH are readmitted within 1 year of receiving their…

Clinical stage pharmaceutical company Corbus Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has approved its investigational new drug (IND) application allowing the company to begin a phase 2 clinical study to evaluate its treatment for diffuse cutaneous systemic sclerosis called Resunab. The phase 2 clinical trial…

A lot can change in five years, especially when someone has chronic thromboembolic pulmonary hypertension (CTEPH). A group of doctors at the University of Würzburg and Katharinen-Hospital Unna in Germany followed a 68-year-old woman for five years, from the time of her visiting the clinic with shortness of…

Actelion Ltd. will present the latest data from its pivotal phase III trial to evaluate selexipag (Uptravi) for the treatment of pulmonary arterial hypertension (PAH) at the American College of Cardiology (ACC) Congress, which is taking place on March 15 in San Diego. The company…

In a recent study entitled “Prevalence and Impact of Pulmonary Hypertension on Patients With Aortic Stenosis Undergoing Transcatheter Aortic Valve Replacement,” a team of MDs reported that pulmonary hypertension (PH) is an independent factor capable of predicting patient outcomes after Transcatheter aortic valve replacement surgery. The…

In a new case-report study entitled “Dramatic and sustained responsiveness of pulmonary Langerhans cell histiocytosis-associated pulmonary hypertension to vasodilator therapy,” authors describe vasodilators’ positive effects in treating Pulmonary Langerhans cell histiocytosis patients with known pulmonary hypertension. The study was published in the journal Respiratory Medicine…